Trial Profile

A phase 3 pivotal clinical study of Haduvio in chronic cough in IPF

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 07 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nalbuphine (Primary)
Indications Cough
Focus Registrational; Therapeutic Use
Sponsors Trevi Therapeutics

Most Recent Events

25 Feb 2025 According to a Trevi Therapeutics media release, the results from CORAL study will help us determine the optimal doses of Haduvio to move into pivotal Phase 3 program.
18 Aug 2022 New trial record
11 Aug 2022 According to a Trevi Therapeutics media release, the company is actively preparing for this trial in chronic cough in IPF and are looking forward to discussing the program and trial plan with the FDA at a meeting scheduled for this quarter.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com